Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)

References

• Diego S, DassaultSystèmes BIOVIA, 2020. Discovery studio modeling environment, release 2020. DassaultSystèmes; b) Dias MVB, Tyrakis P, Domingues RR, Leme AFP, Blundell TL, et al. Mycobacterium tuberculosis Dihydrofolate Reductase Reveals Two Conformational States and a Possible Low Affinity Mechanism to Antifolate Drugs. Structure. 2014;22:94-103;c) Blakley RL, et al. Eukaryotic dihydrofolate reductase. AdvEnzymolRelat Areas Mol Biol. 1995;70:23–102.
   Google Scholar
• Heaslet H, Harris M, Fahnoe K, et al. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim. Proteins. 2009;76(3):706–717.
   PubMed Web of Science ®Google Scholar
• Hong W, Wang Y, Chang Z, et al. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling. Sci Rep. 2015;16(1):15328.
   Google Scholar
• Srinivasan B, Tonddast-Navaei S, Roy A, et al. Chemical space of Escherichia coli dihydrofolate reductase inhibitors: new approaches for discovering novel drugs for old bugs. Med Res Rev. 2019;39(2):684–705.
   PubMed Web of Science ®Google Scholar
• Baird JK, et al. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352(15):1565–1577.
   PubMed Web of Science ®Google Scholar
• Fidock DA, Rosenthal PJ, Croft SL, et al. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004;3(6):509–520.
   PubMed Web of Science ®Google Scholar
• Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J. 2013;42(2):504–512.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Sauvageot D, Banda HT, et al. Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health. 2005;10:723–733.
   PubMed Web of Science ®Google Scholar
• Huennekens FM, et al. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul. 1994; 34: 397–419.
   PubMedGoogle Scholar
• Takimoto CH, Allegra CJ, et al. New antifolates in clinical development. Oncol. 1995;9:649–656.
   Google Scholar
• Huang DB, Noviello S, Blaser B, et al. A pooled analysis of the safety and efficacy of iclaprim versus vancomycin for the treatment of acute bacterial skin and skin structure infection in patients with intravenous drug use: phase 3 REVIVE studies. Clin Ther. 2019;41(6):1090–1096.
   PubMed Web of Science ®Google Scholar
• Galassi R, Oumarou CS, Burini A, et al. A study on the inhibition of dihydrofolate reductase (DHFR) from Escherichia coli by gold(i) phosphane compounds. X-ray crystal structures of (4,5-dichloro-1H-imidazolate-1-yl)-triphenylphosphane-gold(i) and (4,5-dicyano-1H-imidazolate-1-yl)-triphenylphosphane-gold(i). Dalton Trans. 2015;44(7):3043–3056.
   PubMed Web of Science ®Google Scholar
• Hao M, Zhao W, Zhang L, et al. Low folate levels are associated with methylation-mediated transcriptional repression of miR-203 and miR-375 during cervical carcinogenesis. Oncol Lett. 2016;11(6):3863–3869.
   PubMed Web of Science ®Google Scholar
• Schnell JR, Dyson HJ, Wright PE, et al. structure, dynamics, and catalytic function of dihydrofolate reductase, Annu. Rev Biophys Biomol Struct. 2004;33(1):119–140.
   PubMedGoogle Scholar
• Wang M, Yang J, Yuan M, et al. Synthesis and antiproliferative activity of a series of novel 6- substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase. Eur J Med Chem. 2017;128:88–97.
   PubMed Web of Science ®Google Scholar
• Rashood A, Hassan ST, El-Messery GS, et al. Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors. Lett. 2014;24(18):4557–4567.
   Google Scholar
• Mhashal AR, Vardi-Kilshtain A, Kohen A, et al. The role of the Met20 loop in the hydride transfer in Escherichia coli dihydrofolate reductase. J Biol Chem. 2017;292(34):14229–14239.
   PubMed Web of Science ®Google Scholar
• Burchall JJ, et al. The development of the diaminopyrimidines. JAntimicrobChemother. 1979;5:3–14.
   Google Scholar
• Darrell JH, Garrod LP, Waterworth PM, et al. Trimethoprim: laboratory and clinical studies. J ClinPathol. 1968;21. 202–209.
   Google Scholar
• Hawser S, Lociuro S, Islam K, et al. Dihydrofolate reductase inhibitors as antibacterial agents, Biochem. Pharmacol. 2006;7(1):941–948.
   Google Scholar
• Schneider P, Hawser S, Islam K, et al. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett. 2003;13(23):4217–4221.
   PubMed Web of Science ®Google Scholar
• Locher HH, Schlunegger H, Hartman PG, et al. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother. 1996;40(6):1376–1381.
   PubMed Web of Science ®Google Scholar
• Dhople AM, et al. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J Antimicrob Chemother. 2001;47:93–96.
   PubMed Web of Science ®Google Scholar
• Dhople AM, et al. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 2002;19(1):71–74.
   PubMed Web of Science ®Google Scholar
• Hutchings BL, Mowat JH, Oleson JJ, et al. Pteroylaspartic acid, an antagonist for pteroylglutamic acid. J Biol Chem. 1947;170(1):323–328.
   Web of Science ®Google Scholar
• Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin). N Engl J Med. 1948;238(23):787–793.
   PubMed Web of Science ®Google Scholar
• Gubner R, August S, Ginsberg V, et al. Therapeutic suppression of tissue reactivity 2. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951;221:176–182.
   PubMed Web of Science ®Google Scholar
• Kremer JM, et al. Toward a better understanding of methotrexate. Arthritis Rheumatol. 2004;50(5):1370–1382.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Longo DL, et al. Cancer chemotherapy and biotherapy. principles and practice. 5th. Philadelphia PA: Wolters Kluwer, Lippincott Williams & Wilkins; 2011.
   Google Scholar
• Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020;18(5):286–298.
   PubMed Web of Science ®Google Scholar
• Atanasov AG, Zotchev SB, Dirsch VM, et al. Natural products in drug discovery: advances and opportunities, Nat. Rev Drug Discov. 2021;20(3):200–216.
   PubMed Web of Science ®Google Scholar
• Shen BA. New golden age of natural products drug discovery. Cell. 2015;163(6):1297–1300.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Fusetani N, et al. Enzyme inhibitors from marine invertebrates. J Nat Prod. 2007;70(4):689–710.
   PubMed Web of Science ®Google Scholar
• Kalogris C, Garulli C, Pietrella L, et al. Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. Biochem Pharm. 2014;90(3):226–234.
   PubMed Web of Science ®Google Scholar
• Albalawi MAD, Bashir NAO, Tawfik A, et al. Anticancer and antifolate activities of extracts of six saudi arabian wild plants used in folk medicine. J Life Sci. 2015;9. 334–340.
   Google Scholar
• Hobani Y, Jerah A, Bidwai A, et al. A comparative molecular docking study of curcumin and methotrexate to dihydrofolate reductase. Bioinformation. 2017;13(3):63–66.
   PubMed Web of Science ®Google Scholar
• Raimondi MV, Randazzo O, Franca ML, et al. DHFR inhibitors: reading the past for discovering novel anticancer agents. Molecules. 2019;24(6):1140.
   PubMed Web of Science ®Google Scholar
• Desai NC, Trivedi AR, Khedkar VM, et al. Preparation, biological evaluation and molecular docking study of imidazolyldihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors. Bioorg Med Chem Lett. 2016;26(16):4030–4035.
   PubMed Web of Science ®Google Scholar
• Patel TS, Vanparia SF, Patel UH, et al. Novel 2,3-disubstituted quinazoline-4(3H)-one molecules derived from amino acid linked sulphonamide as a potent malarial antifolates for DHFR inhibition. Eur J Med Chem. 2017;1(29):251–265.
   Google Scholar
• Thakkar SS, Thakor P, Doshi H, et al. 1,2,4-Triazole and 1,3,4-oxadiazole analogues: synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities. Bioorg Med Chem. 2017;25(15):4064–4075.
   PubMed Web of Science ®Google Scholar
• Thakkar SS, Thakor P, Ray A, et al. Benzothiazole analogues: synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities. Bioorg Med Chem. 2017;25(20):5396–5406.
   PubMed Web of Science ®Google Scholar
• Shah K, Lin X, Queener SF, et al. Targeting species specific amino acid residues: design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents Bioorg. Med Chem. 2018;26:2640–2650.
   Web of Science ®Google Scholar
• Sharma K, Tanwar O, Sharma S, et al. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents. Bioorg Chem. 2018;80:319–333.
   PubMed Web of Science ®Google Scholar
• Sharma K, Tanwara O, Deora GS, et al. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular Agents. Bioorg Med Chem. 2019;27:1421–1429.
   PubMed Web of Science ®Google Scholar
• Yang X, Wedajo W, Yamada Y, et al. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity. Eur J Med Chem. 2018;144:262–276.
   PubMed Web of Science ®Google Scholar
• Shah K, Queenerb S, Codyc V, et al. Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection. Bioorg Med Chem Lett. 2019;29(15):1874–1880.
   PubMed Web of Science ®Google Scholar
• Metwally NH, Mohamed MS, et al. New imidazolone derivatives comprising a benzoate or sulfonamide moiety as anti-inflammatory and antibacterial inhibitors: design, synthesis, selective COX-2, DHFR and molecular-modeling study. Bioorg Chem. 2020;99:03438.
   Web of Science ®Google Scholar
• Omar AM, Alswah M, Ahmed HEA, et al. Antimicrobial screening and pharmacokinetic profiling of novel phenyl- [1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B. Bioorg Chem. 2020;96:103656.
   PubMed Web of Science ®Google Scholar
• Kronenbergera T, Ferreirac GM, de Souzad ADF, et al. Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors. Bioorg Med Chem. 2020;28(15):115600.
   PubMed Web of Science ®Google Scholar
• He J, Qiao W, An Q, et al. Dihydrofolate reductase inhibitors for use as antimicrobial agents. Eur J Med Chem. 2020;195:112268.
   PubMed Web of Science ®Google Scholar
• El-Messery SM, Hassan GS, Nagi MN, et al. Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassicalantifolates, Bioorg. Med Chem Lett. 2016;26(19):4815–4823.
   PubMed Web of Science ®Google Scholar
• Zhou X, Lin K, Ma X, et al. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors. Eur J Med Chem. 2017;125:1279–1288.
   PubMed Web of Science ®Google Scholar
• El-Gazzar YI, Georgey HH, El-Messery SM, et al. Synthesis, biological evaluation and molecular modeling study of new (1,2,4-triazole or 1,3,4-thiadiazole)-methylthio-derivatives of quinazolin-4(3H)-one as DHFR inhibitors. Bioorg Chem. 2017;72:282–292.
   PubMed Web of Science ®Google Scholar
• Ewida MA, Abou El Ella DA, DS L, et al. Thiazolo[4,5-d]pyridazine analogues as a new class of dihydrofolate reductase (DHFR) inhibitors: synthesis, biological evaluation and molecular modeling study, Bioorg. Chem. 2017;74:228–237.
   Web of Science ®Google Scholar
• Li H, Fang F, Liu Y, et al. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon Bridge. Bioorg Med Chem. 2018;26(9):2674–2685.
   PubMed Web of Science ®Google Scholar
• Ewida MA, Abou El Ella DA, DS L, et al. Imidazo[2′,1′:2,3]thiazolo[4,5-d]pyridazinone as a new scaffold of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study. Bioorg Chem. 2018;80:11–23.
   PubMed Web of Science ®Google Scholar
• Francesconi V, Giovannini L, Santucci M, et al. Synthesis, biological evaluation and molecular modeling of novel azaspirodihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). Eur J Med Chem. 2018;155:229–243.
   PubMed Web of Science ®Google Scholar
• Abdelaziz OA, El Husseiny WM, Selim KB, et al. Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d] pyrimidines: synthesis, antitumor activity and molecular modeling study. Bioorg Chem. 2019;90:103076.
   PubMed Web of Science ®Google Scholar
• Melacure therapeutics. Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors. WO2002/068397A1.
   Google Scholar
• Essential therapeutics. Fused pyrimidine DHFR inhibitors as antibacterial. WO2003/0022064A3.
   Google Scholar
• Mcmaster university. Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reductase; screening assay for the identifications of novel therapeutics and their cellular targets. WO2004/069255A3.
   Google Scholar
• Hallberg A 2,4-diamino quinazoline and pyridopyrimidine ester derivatives as dihydrofolate reductase inhibitors. US2006/0111376A1.
   Google Scholar
• Chroma therapeutics LTD. Pyrimidine derivatives useful as DHFR inhibitors. WO2007/129020A1.
   Google Scholar
• Davidson AH DHFR enzyme inhibitors. US2009/0118311A1.
   Google Scholar
• Auspex pharmaceuticals. Diaminoquinazoline inhibitors of dihydrofolate reductase. US2010/0150896A1.
   Google Scholar
• Trius therapeutics. Dihydrofolate reductase inhibitors. WO2011/153310A1.
   Google Scholar
• Chelsea therapeutics, INC. Enzyme inhibiting compounds. WO2011/056957A2.
   Google Scholar
• Cidara therapeutics, INC. Small molecule inhibitors of dihydrofolate reductase. WO2016/201219A1.
   Google Scholar
• Isis innovation limited. Dihydrofolate reductase inhibitors. WO2001/0153276A1.
   Google Scholar
• Vyera pharmaceuticals, LLC. DHFR inhibitors, compositions and methods related there to. WO2019/032458A1.
   Google Scholar
• Dana-farber cancer institute. 2,4-diamino-5-[5’-substituted-benzyl]pyrimidine and 2,4-diamino-6-[5’-substituted-benzyl]quinazolines. WO2004/082613A2.
   Google Scholar
• Dana-farber cancer institute. Pharmaceutically active compounds and methods of use thereof. US2004/0242614A1.
   Google Scholar
• Stoicescu D Novel inhibitors of folic acid dependent enzymes. US2008/0207652A1.
   Google Scholar
• University of Connecticut. Inhibitors of dihydrofolate reductase with antibacterial, antiprotozoal, antifungal and anticancer properties. WO2009/025919A2.
   Google Scholar
• Dreier J Method for the treatment of anthrax infections. US2010/0305119A1.
   Google Scholar
• University of Connecticut. Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase. WO2013/070620A1.
   Google Scholar
• Duquesne university of the holy spirit. Substituted pyrimidine compounds and methods of use and manufacture. WO2016/022881.
   Google Scholar
• The university of Connecticut. Zwitterionic propargyl-linked antifolates useful for treating bacterial infections. WO2017/120575A1.
   Google Scholar
• National science and technology development agency. Antimalarial pyrimidine derivatives and methods of making and using them. US20040180913A1.
   Google Scholar